Tender detail

Non-exclusive rebate agreement for risedronic acid medicines

Summary

DAK-Gesundheit intends to conclude rebate agreements for medicines containing risedronic acid, excluding FTA medicines in 5 mg and 75 mg strengths (ATC M05BA07). The agreements will take effect on 1 December 2026 and run until 30 November 2028, with an option to extend for one 12-month period; they will end earlier if an exclusive agreement for the active substance takes effect.

Reference number
dedc7385-0083-416e-99c2-ab0448362602
Buyer
Country
Germany (DEU)
Procedure
Open procedure
CPV
33600000 Pharmaceutical products
Deadline
2029-10-05
Status
Open
Contract subject
Supplies
Estimated value
1,00 EUR
Source
DEU_BKMS

More tender information after sign-in

The public view shows key tender details. Sign in to open official links, documents and AI tender support.